> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Whole Slide Imaging in Tox Studies
- URL: https://www.fdaweb.com/whole-slide-imaging-in-tox-studies/
- Published: 2022-04-07T12:00:00.000Z
- Updated: 2026-09-14T17:39:43.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5151545

FDA has published a draft guidance, *Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers*, to provide information to sponsors and nonclinical laboratories about using and managing whole slide images used during histopathology assessment and/or pathology peer review performed for good laboratory practice (GLP)-compliant nonclinical toxicology studies using non-human specimens. The [document](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-whole-slide-imaging-nonclinical-toxicology-studies-questions-and-answers?ref=fdaweb.com) says that when whole slide imaging is used as part of a nonclinical study conducted in compliance with the GLP regulations, adequate documentation is critical.

“FDA’s expectations regarding documentation practices during generation, use, and retention of whole slide images have not been clearly defined and vary among nonclinical testing facilities,” the guidance says. “This question-and-answer document is intended to clarify FDA’s recommendations concerning the management, documentation, and use of whole slide imaging in histopathology assessment and/or pathology peer review for nonclinical studies conducted in compliance with the GLP regulations.”